This last finding is further evidence that the increased rate of deamidation-regulated degradation of Bcl-xL is an important target of the increase in pH that occurs in response to treatment with DNA-damaging agents in susceptible tumor cells. This evidence concerns the gene BCL2L1 and neoplasm.